Sanofi Market Cap 2010-2024 | SNY

Sanofi market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Sanofi market cap as of February 14, 2025 is $134.18B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $134.176B $44.458B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $826.256B 66.95
Novo Nordisk (NVO) Denmark $391.178B 26.50
Johnson & Johnson (JNJ) United States $369.594B 15.37
AbbVie (ABBV) United States $341.005B 19.07
Roche Holding AG (RHHBY) Switzerland $252.630B 0.00
AstraZeneca (AZN) United Kingdom $224.395B 17.61
Merck (MRK) United States $222.734B 11.52
Novartis AG (NVS) Switzerland $218.667B 13.70
Pfizer (PFE) United States $146.378B 8.31
Bayer (BAYRY) Germany $21.810B 3.49
Innoviva (INVA) United States $1.143B 9.51